Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...
Corbus Pharmaceuticals reports no neuropsychiatric events in CRB-913 trial, advancing to multiple ascending dose phase. Study completion projected for Q3 2025. Corbus Pharmaceuticals Holdings Inc. has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback